Company ProfilePremium

TransEnterix, Inc.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
TransEnterix, Inc. - Healthcare showcase

Year Founded & Workforce

2006

200 Employees

Industry

Healthcare

Services

Surgical Robots
T

TransEnterix, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

TransEnterix, Inc. Overview

Company Headquarters: North Carolina, US

Founded: 2006

Workforce: ~200

Company Working: TransEnterix, Inc. (TransEnterix) is a medical device company. It engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgeries. The company offers Senhance Surgical Robotic System, a multi-port robotic system which gives surgeons the precision to perform surgeries with more accuracy. TransEnterix has also developed another system named SurgiBot System, which gives robotically enhanced laparoscopic surgical platform to healthcare professionals.

Strategy

TransEnterix focuses on digitizing the interface between the surgeon and patient in laparoscopy to increase control and reduce surgical inconsistency in the healthcare industry. The company is a pioneer in surgical robotics, which aims to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options.

Company Snapshot

$0M

Revenue

200

Employees

2006

Founded

North Carolina, US

Headquarters

SWOT Analysis

Strengths

  • Strong R&D
  • Skilled workforce

Weaknesses

  • Inefficient financial planning

Opportunities

  • Acquisitions to enhance the company’s product portfolio

Threats

  • Stringent government regulations

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
January 2019Product ApprovalTransEnterix received FDA 510(k) clearance for its Senhance Ultrasonic System. The addition of ultrasonic technology to Senhance system enhance its capabilities to effectively ligate and divide tissue and minimize thermal injury to surrounding structures.
October 2018Product ApprovalTransEnterix received FDA 510(k) clearance for or 3mm Diameter Instruments which helps in advancing minimally invasive capabilities within digital laparoscopy.
March 2017ExpansionTransEnterix announced the expansion of its application areas for Senhance robotic surgical system into robotic hernia repair. The robotic hernia repair with the Senhance system enhances precision and safety during hernial repair surgical procedures.
January 2017InvestmentTransEnterix has received an increased equity investment from SOFAR SpA, which is valued at EUR 5 million, or approximately USD 5.2 million.
November 2016AgreementTransEnterix entered into an agreement with Getz Healthcare for a distribution agreement for Australia and New Zealand for Senhance surgical robotic system.

Product Offering

  • TransEnterix, Inc.
    • Surgical Robots

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 0 Mn in 2015 to USD 7.1 Mn in 2017.
TransEnterix, Inc. — By Business Segment
Series (USD Mn)201520162017
Sales01.57.1
R&D Expenditure29.729.322

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.